Key Points
- Enliven Therapeutics CFO Benjamin Hohl sold 6,018 shares at an average price of $50.35, totaling $303,006.30. The transaction, conducted under a pre-arranged Rule 10b5-1 plan, reduced his holdings by 13.67% to 38,000 shares.
- ELVN recently traded at $48.87, with a market capitalization of approximately $3.58 billion, after reaching a 52-week range of $14.78 to $62.32. The company reported a quarterly loss of $0.49 per share, missing the $0.39 consensus estimate.
- Analyst sentiment remains broadly positive, with eight Buy ratings and one Sell rating and a consensus price target of $75.00. Institutional investors own approximately 95.08% of the company’s stock.
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 6,018 shares of the company's stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $50.35, for a total value of $303,006.30. Following the sale, the chief financial officer owned 38,000 shares of the company's stock, valued at $1,913,300. This trade represents a 13.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Benjamin Hohl also recently made the following trade(s):
- On Monday, August 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The stock was sold at an average price of $58.58, for a total value of $352,534.44.
- On Friday, July 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The shares were sold at an average price of $52.64, for a total transaction of $316,787.52.
Enliven Therapeutics Stock Performance
Shares of ELVN opened at $48.87 on Tuesday. The stock has a market capitalization of $3.58 billion, a P/E ratio of -29.26 and a beta of 0.30. The company's fifty day moving average is $56.39 and its two-hundred day moving average is $46.31. Enliven Therapeutics, Inc. has a 1 year low of $14.78 and a 1 year high of $62.32.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.10). Sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.69 EPS for the current year.
Wall Street Analyst Weigh In
ELVN has been the subject of several analyst reports. Mizuho increased their price target on shares of Enliven Therapeutics from $62.00 to $73.00 and gave the stock an "outperform" rating in a report on Tuesday, August 18th. William Blair initiated coverage on Enliven Therapeutics in a report on Tuesday, August 18th. They issued an "outperform" rating on the stock. Guggenheim dropped their target price on Enliven Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a research report on Thursday, August 6th. The Goldman Sachs Group raised their price target on Enliven Therapeutics from $67.00 to $80.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Finally, JonesTrading lifted their price target on Enliven Therapeutics from $45.00 to $70.00 and gave the company a "buy" rating in a research note on Monday, June 29th. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $75.00.
Get Our Latest Stock Analysis on ELVN
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in the company. KBC Group NV purchased a new stake in shares of Enliven Therapeutics in the 1st quarter worth about $38,000. State of Wyoming acquired a new stake in Enliven Therapeutics in the 2nd quarter valued at about $96,000. FNY Investment Advisers LLC purchased a new position in Enliven Therapeutics during the 2nd quarter valued at about $126,000. WINTON GROUP Ltd purchased a new position in Enliven Therapeutics during the 2nd quarter valued at about $228,000. Finally, Squarepoint Ops LLC purchased a new position in Enliven Therapeutics during the 2nd quarter valued at about $259,000. Institutional investors and hedge funds own 95.08% of the company's stock.
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for the treatment of cancer. The company applies a precision oncology approach, seeking to create targeted therapies that may offer improved efficacy, safety, durability and convenience compared with existing treatments.
Enliven's pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for patients with chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for the treatment of HER2-driven solid tumors.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
